CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus‐positive patients with resected hepatocellular carcinoma

This study investigated whether the expression of CD44 variant 9 (CD44v9) might be a functional marker of tumor‐initiating stem‐like cells in primary hepatocellular carcinomas (HCCs) of hepatitis C virus (HCV)(+) patients and provide an indicator of patient survival, as well as associated mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakehashi, Anna, Ishii, Naomi, Sugihara, Eiji, Gi, Min, Saya, Hideyuki, Wanibuchi, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970827/
https://www.ncbi.nlm.nih.gov/pubmed/26882440
http://dx.doi.org/10.1111/cas.12908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970827/
https://www.ncbi.nlm.nih.gov/pubmed/26882440
http://dx.doi.org/10.1111/cas.12908

Ejemplares similares